Telix Pharmaceuticals (ASX:TLX): What Do Q3 Revenue Growth and New Imaging Milestones Mean for 2026?

Aditi Sarkar

27 October 2026 10:33 PM AEDT

Telix Pharmaceuticals (ASX:TLX): What Do Q3 Revenue Growth and New Imaging Milestones Mean for 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals (ASX:TLX) reported Q3 2026 group revenue of USD 245mn, up 19% YoY.
Precision Medicine revenue rose 30% YoY to USD 201mn, while manufacturing revenue was USD 44mn.
H1 2026 revenue reached USD 477mn; profit after tax was USD 38mn and operating cash flow USD 23mn.
FY26 revenue guidance remains USD 950–970mn, with research and development spending guided at USD 240–260mn.

Telix Pharmaceuticals (ASX:TLX) develops and commercialises radiopharmaceutical products used in cancer imaging and is advancing therapeutic candidates through clinical trials. Its latest quarterly update reported higher sales of prostate cancer imaging products alongside the U.S. launch of a brain cancer imaging agent. The company is also progressing a proposed transaction involving radiopharmaceutical manufacturer ITM while maintaining its full-year revenue guidance.

Company Business

Telix Pharmaceuticals (ASX:TLX) operates across Precision Medicine, Therapeutics and Telix Manufacturing Solutions (TMS). Precision Medicine markets molecular imaging products that help clinicians identify or assess cancer. Illuccix and Gozellix are gallium-68-labelled prostate-specific membrane antigen imaging products used in positron emission tomography (PET). The division has an established U.S. commercial base and international regulatory programs.

The Therapeutics division investigates targeted radiation treatments for prostate, kidney and brain cancers. Its development projects require clinical evidence and regulatory review before any commercialisation. TMS supplies radiopharmaceutical manufacturing, isotope production, pharmacy and distribution capabilities, including the RLS Radiopharmacies network. This infrastructure is relevant because radioisotopes have specialised production and logistics requirements, creating operational dependencies distinct from conventional pharmaceuticals.

Recent Development

In October 2026, Telix Pharmaceuticals (ASX:TLX) reported third-quarter revenue of USD 245mn for the period ended 30 September. Precision Medicine generated USD 201mn, compared with USD 155mn in Q3 2025. The company attributed the increase primarily to sales of Illuccix and Gozellix. U.S. dose volumes rose 1% quarter-on-quarter; the company identified seasonal effects and a higher September sales exit rate.

Pixclara received U.S. Food and Drug Administration approval for glioma imaging, and the first U.S. patients were dosed in October. Telix also completed enrolment of 350 participants in its Phase 3 BiPASS prostate imaging study. Separately, a proposed merger with ITM includes USD 1.65bn of upfront consideration on a cash-free, debt-free basis and remains subject to shareholder approval and other conditions. A shareholder meeting is expected in December 2026.

The company is preparing a U.S. regulatory resubmission for Zircaix, its kidney cancer imaging candidate, after addressing third-party manufacturing observations. That application remains unresolved and should not be treated as an approval. Clinical development continues across the ProstACT Global, LUTEON and brain cancer treatment programs.

Financial Performance and Sector Context

Telix Pharmaceuticals (ASX:TLX) recorded Q3 group revenue of USD 245mn, up from USD 206mn a year earlier, but below USD 247mn in Q2 2026. TMS third-party revenue was USD 44mn, versus USD 47mn in Q3 2025 and USD 45mn in Q2. Quarterly revenue provides a commercial indicator but does not itself establish net profitability, which was not included in the Q3 sales comparison.

For H1 2026, group revenue was USD 477mn compared with USD 390mn in H1 2025. Gross profit increased to USD 260mn from USD 209mn, while the gross margin was 55%. Adjusted EBITDA increased to USD 52mn from USD 21mn. Statutory profit after tax was USD 38mn, compared with a USD 2mn loss a year earlier. Results included USD 40mn of collaboration-related other income, making the distinction between recurring product revenue and other income important.

H1 operating cash inflow was USD 23mn, versus USD 18mn in the prior corresponding period, and cash stood at USD 252mn at 30 June. Research and development expenditure increased to USD 124mn from USD 82mn. Telix expects FY26 revenue of USD 950–970mn and other income of USD 40mn, with total revenue and other income exceeding USD 1bn. Revised FY26 research spending guidance is USD 240–260mn.

Risks to Consider

Telix Pharmaceuticals (ASX:TLX) faces clinical trial, regulatory, manufacturing and reimbursement risks. Planned product registrations may be delayed or rejected, while the proposed ITM combination requires approvals and integration execution. Commercial imaging demand depends partly on clinical adoption, isotope availability, specialist distribution and payment arrangements. R&D expenditure, refinancing obligations and potential financing transactions also require attention, particularly where commercial cash generation and pipeline investment occur concurrently.

What to Watch Next

Upcoming disclosures from Telix Pharmaceuticals (ASX:TLX) include further Illuccix and Gozellix sales trends, Pixclara launch volumes, Zircaix resubmission progress and the proposed ITM merger vote. The company has scheduled a capital markets day for November 2026. The next financial reporting periods should clarify how revenue growth, TMS spending and pipeline investment affect cash generation and margins. Investigators are also expected to report results from several therapeutic studies as their clinical timelines advance.

Key Insights

Telix Pharmaceuticals (ASX:TLX) reported higher Q3 year-on-year revenue, driven by its existing prostate imaging portfolio, while H1 results showed positive statutory profit and operating cash flow. Its development program and proposed manufacturing transaction introduce additional potential milestones but also execution and regulatory obligations. FY26 revenue guidance, R&D spending and progress towards further approvals remain measurable points for subsequent company updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.